Skip to main content

Table 3 Clinical characteristics of patients who have survived over 5 years

From: Survival past five years with advanced, EGFR-mutated or ALK-rearranged non-small cell lung cancer—is there a “tail plateau” in the survival curve of these patients?

Characteristics All EGFR-Mutated ALK-Rearranged
N = 46 % N = 37 % N = 9 %
Age
 Median (range), years 62 (35–80) 64 (50–80) 51 (35–74)
Sex
 Male 19 41.3 14 37.8 5 55.5
 Female 27 58.7 23 62.1 4 44.4
Smoking status
 Never-smoker 20 43.5 16 43.2 4 44.4
 Current or former smoker 23 50 18 48.6 5 55.5
 Unknown 3 6.5 3 8.1 0 0
Pack-years, median(range) 32(2–114) 32(2–114) 29.5(13–48)
ECOG performance status
 0 33 71.7 27 72.9 6 66.6
 1 10 21.7 8 21.6 2 22.2
 2 0 0 0 0 0 0
  > 2 2 4.3 1 2.7 1 11.1
 Unknown 1 2.1 1 2.7 0 0
Tumor histology
 Adenocarcinoma 42 91.3 34 91.8 8 88.8
 NSCLC, NOS 1 2.1 0 0 1 11.1
 Unknown 3 6.5 3 8.1 0 0
Stage
 Relapse 25 54.3 22 59.4 3 33.3
 III 3 6.5 2 5.4 1 11.1
 IV 18 39.1 13 35.1 5 55.5
Presence of extrathoracic metastases
 Yes 13 28.2 9 24.3 4 44.4
 No 33 71.1 28 75.6 5 55.5
Presence of brain metastases
 Yes 5 10.8 2 5.4 3 33.3
 No 41 89.1 35 94.5 6 66.6